Pharmaceutical.Report

Marium Qaiser, a Global Health and Life Sciences Consultant in drugs research and manufacture at GSK, explains the emergence of antimicrobial resistance and its effects on human health in low and middle-income countries. She emphasizes the need for multi-pronged approaches to address the AMR crisis.

To read more, click here: https://bit.ly/3Q5MzO1

Exploring the Rising Global Concern of Antimicrobial Resistance Explore the escalating global concern of antimicrobial resistance, its ramifications for health, and potential solutions in this comprehensive article.

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injection was delivered successfully to all 23 participants and was well tolerated.

Click here to read the full article now: https://bit.ly/3ty9gCS

Halozyme Announces Positive Clinical Data of its High-Volume Halozyme Therapeutics, Inc.announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic

BioMap announced a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform.

Be in the know and click here to learn more about this news: https://bit.ly/3tyOq6C

BioMap Establishes a Strategic Collaboration with Sanofi BioMap announced a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery

Indivior, a leading addiction treatment company, has gained exclusive global rights to develop, manufacture, and commercialize 昱展新藥 Alar Pharmaceuticals Inc. Inc.'s portfolio of long-acting injectable formulations that release a prodrug of buprenorphine at varying durations, including its lead long-acting injectable candidate, ALA-1000.

Click the link below to read the full news:
https://bit.ly/3FgJXYS

Indivior Enters an Exclusive Licensing Agreement with Alar Indivior PLC a leading addiction treatment company, announced that it has gained exclusive global rights to develop,

MEDIA 7's The Pharmaceutical.Report invites you to be a part of the 9th Pharma Packaging and Labeling Innovation Forum 2023, set to take place in Berlin, Germany, from October 5th to 6th, 2023.

Join this leading event to gain valuable insights on key industry challenges for material & design innovations, sustainability, branding & marketing, as well as inspirational & active packaging.

More details are available at: https://bit.ly/3RJhIcI

Featured Speakers: Nurit Nahum, PhD | Dario Kulić | Michiel van den Berg | Christina Montjoly | Kathrin Gallistl-Burandt | Anne Uusitalo | Simon Cavanagh | Steven Brookes | Chiara T. | Sabine Faber, PhD and many others..

Date- 5-6th Oct, 2023
Format- In – person
Organizer- BrainLinx

Register now: https://bit.ly/3RJhIcI

9th Pharma Packaging And Labeling Innovation Forum 9th Pharma Packaging And Labeling Innovation Forum 2023 is an executive platform to discuss the industry